November 28, 2023

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target

TOKYO, Japan, 28 Nov 2023: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology...
Read More
May 31, 2023

PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical

TOKYO, Japan, 31 May 2023: – PRISM BioLab, a Japan based biotechnology company with a proprietary...
Read More
January 13, 2023

New study by PRISM Biolab demonstrates rational design of small molecule inhibitors of CTLA-4 and B7-1 protein-protein interaction utilizing only a sequence of a binding peptide

The paper published in the special issue of Pharmaceuticals journal dedicated to “Small Molecules Targeting Protein-Protein...
Read More
October 28, 2022

Pharma Intelligence Award Japan 2022 Commemorative Webinar “PPI Inhibition by Small Molecules: A New Drug Discovery Paradigm”

PRISM BioLab's proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein...
Read More
September 1, 2022

PRISM Biolab Wins Biotech Company of the Year Award of Informa Pharma Intelligence Award 2022

We are pleased to announce that we have won the Biotech company of the year in...
Read More
January 5, 2022

PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech

TOKYO, Japan, 5th Jan. 2022: -- PRISM BioLab, a Japan based biotechnology company with a proprietary...
Read More
November 1, 2021

The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)

Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP) /...
Read More
November 1, 2021

PRISM BioLab raised 100 million yen in Series C funding from Eisai

PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today...
Read More
October 28, 2021

The paper of peptidomimetics is published in ACS Omega

This paper presents the new method to analyze how peptidomimetics scaffold mimic the actual peptide, and PRISM’s scaffold advantage is confirmed.
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
Read More
September 9, 2021

PRISM BioLab raised 1.3 billion yen in Series C funding

PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today...
Read More
1 2 3